The Kaplan–Meier survival analysis and the long-rank test demonstrated a higher survival in females than in males, even if borderline significant ( p = 0.06) (Fig. 1 ); the survival rates at 5 year were 85.6% of males and 92.4% of females, respectively.
An increasing trend was also observed for mycophenolic acid, whose prevalence increased from 0.8 to 11.1% in the 2008–2017 period.
The calcium channel blockers (CCB) dihydropyridine derivatives were the only ones characterized by a decreasing trend from 32.7 to 28.2%, with a higher percentage of users (34%) observed in the 2013–2014 period.